<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Marker Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/marker-therapeutics-inc</link>
<description>Latest news and press releases for Marker Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Wed, 18 Mar 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/marker-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo68359d1b78dffbe2df107723.webp</url>
<title>Marker Therapeutics Inc</title>
<link>https://6ix.com/company/marker-therapeutics-inc</link>
</image>
<item>
<title>Marker Therapeutics Reports Year-End 2025 Corporate and Financial Results</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-reports-year-end-2025-corporate-and-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-reports-year-end-2025-corporate-and-financial-results</guid>
<pubDate>Wed, 18 Mar 2026 04:00:00 GMT</pubDate>
<description>Phase 1 APOLLO data update demonstrated encouraging clinical activity with a 66% objective response rate in relapsed non-Hodgkin lymphoma, including 50%</description>
</item>
<item>
<title>Marker Therapeutics to Present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-to-present-at-the-oppenheimer-36th-annual-healthcare-life-sciences-conference</guid>
<pubDate>Wed, 18 Feb 2026 13:00:00 GMT</pubDate>
<description>HOUSTON, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will present at the Oppenheimer 36th Annual Healthcare Life Sciences Conference, being held in a virtual format on February 25-26, 2026. Presentation Details: Event</description>
</item>
<item>
<title>Good Morning America Features Baylor College of Medicine Pancreatic Cancer Study Utilizing Marker Therapeutics’ MAR-T Cell Technology</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/good-morning-america-features-baylor-120000802</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/good-morning-america-features-baylor-120000802</guid>
<pubDate>Mon, 26 Jan 2026 12:00:00 GMT</pubDate>
<description>National broadcast highlights the need for new approaches in one of the deadliest forms of cancerHOUSTON, Jan. 26, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company with the worldwide exclusive license of Multi-Antigen Targeted T cells (also referred to as Multi-Antigen Recognizing T cells, or MAR-T cells, by Marker), a technology developed at Baylor College of Medicine for the treatment of hematologic and solid tumors, today announced th</description>
</item>
<item>
<title>Baylor College of Medicine Publishes Promising Safety and Efficacy Results of Multi-Antigen Targeted T Cells in Patients with Pancreatic Cancer</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/baylor-college-medicine-publishes-promising-120000004</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/baylor-college-medicine-publishes-promising-120000004</guid>
<pubDate>Mon, 05 Jan 2026 12:00:00 GMT</pubDate>
<description>Clinical study from Baylor College of Medicine demonstrates a favorable safety profile and up to 84.6% disease control rate in patients with pancreatic cancer in Arm A of the clinical study Study highlights correlation between the clinical benefit and the expansion and persistence of Multi-Antigen Targeted T cells HOUSTON, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR) is a clinical-stage immuno-oncology Company with the worldwide exclusive license of Multi-Antigen Ta</description>
</item>
<item>
<title>Marker Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-reports-third-quarter-120000903</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-reports-third-quarter-120000903</guid>
<pubDate>Fri, 14 Nov 2025 12:00:00 GMT</pubDate>
<description>APOLLO study showed encouraging overall responses and favorable safety profile in relapsed/refractory B-cell lymphoma MT-601 demonstrated 66% objective response rate with 50% complete response in relapsed Non-Hodgkin lymphoma (NHL) patients in the ongoing APOLLO study First patient treated in Off-the-Shelf program (RAPID study) investigating MAR-T cells in patients with Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS) cGMP manufacturing collaboration established with Cellipont Bios</description>
</item>
<item>
<title>Marker Therapeutics appoints Kathryn Penkus Corzo to Board of Directors</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-appoints-kathryn-penkus-123000996</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-appoints-kathryn-penkus-123000996</guid>
<pubDate>Wed, 05 Nov 2025 12:30:00 GMT</pubDate>
<description>HOUSTON, Nov. 05, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced the appointment of Kathryn Penkus Corzo, R.Ph., MBA to the Company’s Board of Directors, effective November 1, 2025. Ms. Penkus Corzo has vast experience as a biopharma executive, drug developer and independent bo</description>
</item>
<item>
<title>Marker Therapeutics Announces Upcoming Presentations on MT-601 in Relapsed Non-Hodgkin and Hodgkin Lymphoma at the 67th ASH Annual Meeting</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-announces-upcoming-presentations-141500508</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-announces-upcoming-presentations-141500508</guid>
<pubDate>Mon, 03 Nov 2025 14:15:00 GMT</pubDate>
<description>Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphomas showed encouraging preliminary efficacy data MT-601 demonstrated robust safety profile with no dose limiting toxicities (DLTs) or immune-effector cell associated neurotoxicity syndrome (ICANS) in the dose escalation cohort HOUSTON, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immuno</description>
</item>
<item>
<title>Marker Therapeutics Announces First Patient Treated in Off-the-Shelf Program</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-announces-first-patient-113000792</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-announces-first-patient-113000792</guid>
<pubDate>Mon, 06 Oct 2025 11:30:00 GMT</pubDate>
<description>Marker Therapeutics initiated Phase 1 RAPID study to investigate Multi-Antigen Recognizing (MAR) T cells as an Off-the-Shelf (OTS) product to accelerate time to treatment OTS product was well tolerated - safety data consistent with other MAR-T cell studies HOUSTON, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies a</description>
</item>
<item>
<title>Marker Therapeutics to Participate in a Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-participate-fireside-chat-120000989</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-participate-fireside-chat-120000989</guid>
<pubDate>Thu, 28 Aug 2025 12:00:00 GMT</pubDate>
<description>HOUSTON, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a fireside chat at the H.C. Wainwright 27th Annual Global Investment Conference taking place from September 8-10, 2025 in New York. Fireside Cha</description>
</item>
<item>
<title>Marker Therapeutics Provides Update on Phase 1 APOLLO Study Highlighting Encouraging Overall Response Rates in Relapsed Lymphoma</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-provides-phase-1-110000545</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-provides-phase-1-110000545</guid>
<pubDate>Tue, 26 Aug 2025 11:00:00 GMT</pubDate>
<description>Ongoing Phase 1 APOLLO study investigating MT-601 in patients with relapsed B cell lymphoma showed 66% of Non-Hodgkin Lymphoma (NHL) patients achieving objective response rates, with 50% demonstrating complete response (CR) Favorable safety profile observed in study participants with no dose limiting toxicities (DLTs) or immune-effector cell associated neurotoxicity syndrome (ICANS) in the dose escalation cohort Dose expansion phase of study will investigate MT-601 at pre-specified maximum dose</description>
</item>
<item>
<title>Marker Therapeutics to Participate in a Fireside Chat at the Canaccord Genuity 45th Annual Growth Conference</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-participate-fireside-chat-120000214</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-participate-fireside-chat-120000214</guid>
<pubDate>Wed, 30 Jul 2025 12:00:00 GMT</pubDate>
<description>HOUSTON, July 30, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a fireside chat at the Canaccord Genuity 45th Annual Growth Conference taking place from August 12-14, 2025 in Boston, Massachusetts. Fireside C</description>
</item>
<item>
<title>Marker Therapeutics and Cellipont Bioservices Announce Collaboration to Advance cGMP Manufacturing of MT-601, a Multi-Antigen Recognizing T Cell Therapy for Patients with Lymphoma</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-cellipont-bioservices-announce-120000630</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-cellipont-bioservices-announce-120000630</guid>
<pubDate>Tue, 17 Jun 2025 12:00:00 GMT</pubDate>
<description>HOUSTON, June 17, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced a collaboration with Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), for current good manufacturing practice (cGMP) manufacturing of MT-601, Marker’s lead</description>
</item>
<item>
<title>Marker Therapeutics Reports that Lymphodepletion Improves the Expansion and Persistence of Multi-Antigen Recognizing T Cells in Patients with Lymphoma</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-reports-lymphodepletion-improves-120000146</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-reports-lymphodepletion-improves-120000146</guid>
<pubDate>Tue, 20 May 2025 12:00:00 GMT</pubDate>
<description>Preconditioning with lymphodepletion linked to stronger MAR-T cells response and suggests enhanced anti-tumor activity Highest enrollment since study launch underscores momentum and signals a positive trial trajectory Clinical data readout from Phase 1 APOLLO study expected later this year HOUSTON, May 20, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatmen</description>
</item>
<item>
<title>Marker Therapeutics to Spotlight Multi-Antigen Recognizing (MAR)-T Cells in High-Profile Panel on CAR-T Cell Therapies</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-spotlight-multi-antigen-120000164</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-spotlight-multi-antigen-120000164</guid>
<pubDate>Mon, 19 May 2025 12:00:00 GMT</pubDate>
<description>Virtual event with Key Opinion Leaders to discuss cell therapy landscape and shortcomings of CAR-T therapies set for May 28, 2025HOUSTON, May 19, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a live webcast produced by</description>
</item>
<item>
<title>Marker Therapeutics to Present at Canaccord Genuity’s Horizons in Oncology Conference</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-present-canaccord-genuity-120000515</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-present-canaccord-genuity-120000515</guid>
<pubDate>Tue, 01 Apr 2025 12:00:00 GMT</pubDate>
<description>HOUSTON, April 01, 2025 (GLOBE NEWSWIRE) -- MARKER THERAPEUTICS, INC. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumors, today announced that its Chief Executive Officer, Dr. Juan Vera, will participate in a panel discussion at Canaccord Genuity’s Horizons in Oncology Virtual Conference. Dr. Vera will join company executives and key opinion leaders to discus</description>
</item>
<item>
<title>Marker Therapeutics Reports Year-End 2024 Corporate and Financial Results</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-reports-end-2024-124500439</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-reports-end-2024-124500439</guid>
<pubDate>Mon, 31 Mar 2025 12:45:00 GMT</pubDate>
<description>Lead program investigating MT-601 in patients with refractory lymphomas, including anti-CD19 CAR-T cell therapy, demonstrated safety and efficacy in 9 patients with 78% having objective responses, including durable complete responses Secured over $13 million in non-dilutive funding from the Cancer Prevention & Research Institute of Texas (CPRIT) and the National Institute of Health (NIH) Small Business Innovation Research (SBIR) to support pancreatic and lymphoma clinical programs Approval from</description>
</item>
<item>
<title>Marker Therapeutics to Present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-present-h-c-120000529</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-present-h-c-120000529</guid>
<pubDate>Tue, 25 Feb 2025 12:00:00 GMT</pubDate>
<description>HOUSTON, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced that Juan Vera, M.D., President and Chief Executive Officer of Marker Therapeutics, will present at the H.C. Wainwright 3rd Annual Cell Therapy Virtual Conference. This virtual investor event will be held on Febru</description>
</item>
<item>
<title>Marker Therapeutics Announces $16.1 Million Private Placement</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-announces-dollar161-million-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-announces-dollar161-million-private-placement</guid>
<pubDate>Thu, 19 Dec 2024 05:00:00 GMT</pubDate>
<description>Strategic financing supports clinical advancement in Phase 1 APOLLO study investigating MT-601 in patients with lymphoma who relapsed after anti-CD19 CAR-T</description>
</item>
<item>
<title>Marker Therapeutics Provides a Clinical Update on MT-601 in Patients with Lymphoma</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-provides-a-clinical-update-on-mt-601-in-patients-with-lymphoma</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-provides-a-clinical-update-on-mt-601-in-patients-with-lymphoma</guid>
<pubDate>Thu, 19 Dec 2024 05:00:00 GMT</pubDate>
<description>APOLLO study investigating MT-601 in patients with relapsed lymphoma: 78% of patients achieved objective response rates, with 44.4% demonstrating complete</description>
</item>
<item>
<title>Marker Therapeutics Awarded $9.5 Million Grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to Support the Investigation of MT-601 in Patients with Pancreatic Cancer</title>
<link>https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-awarded-dollar95-million-grant-from-the-cancer-prevention-and-research-institute-of-texas-cprit-to-support-the-investigation-of-mt-601-in-patients-with-pancreatic-cancer</link>
<guid isPermaLink="true">https://6ix.com/company/marker-therapeutics-inc/news/marker-therapeutics-awarded-dollar95-million-grant-from-the-cancer-prevention-and-research-institute-of-texas-cprit-to-support-the-investigation-of-mt-601-in-patients-with-pancreatic-cancer</guid>
<pubDate>Tue, 17 Dec 2024 05:00:00 GMT</pubDate>
<description>HOUSTON, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Marker Therapeutics, Inc. (Nasdaq: MRKR), a clinical-stage immuno-oncology company focusing on developing</description>
</item>
</channel>
</rss>